CN105121472A - 抗体/药物缀合物及其使用方法 - Google Patents

抗体/药物缀合物及其使用方法 Download PDF

Info

Publication number
CN105121472A
CN105121472A CN201380069036.9A CN201380069036A CN105121472A CN 105121472 A CN105121472 A CN 105121472A CN 201380069036 A CN201380069036 A CN 201380069036A CN 105121472 A CN105121472 A CN 105121472A
Authority
CN
China
Prior art keywords
chain
conjugate
antibody
cells
phor18
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380069036.9A
Other languages
English (en)
Chinese (zh)
Inventor
卡罗拉·洛伊什纳
赫克托·阿里拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperance Pharmaceuticals Inc
Original Assignee
Esperance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperance Pharmaceuticals Inc filed Critical Esperance Pharmaceuticals Inc
Publication of CN105121472A publication Critical patent/CN105121472A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380069036.9A 2012-10-30 2013-10-30 抗体/药物缀合物及其使用方法 Pending CN105121472A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720257P 2012-10-30 2012-10-30
US61/720,257 2012-10-30
PCT/US2013/067621 WO2014070957A1 (en) 2012-10-30 2013-10-30 Antibody/drug conjugates and methods of use

Publications (1)

Publication Number Publication Date
CN105121472A true CN105121472A (zh) 2015-12-02

Family

ID=50622572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380069036.9A Pending CN105121472A (zh) 2012-10-30 2013-10-30 抗体/药物缀合物及其使用方法

Country Status (11)

Country Link
US (5) US9492563B2 (https=)
EP (2) EP4035685A1 (https=)
JP (1) JP6559066B2 (https=)
KR (2) KR20210090298A (https=)
CN (1) CN105121472A (https=)
AU (2) AU2013337926B2 (https=)
BR (1) BR112015009752A2 (https=)
CA (1) CA2889475A1 (https=)
DK (1) DK2914633T3 (https=)
IL (1) IL238323B2 (https=)
WO (1) WO2014070957A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106248971A (zh) * 2016-08-19 2016-12-21 合肥瀚科迈博生物技术有限公司 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途
CN108779160A (zh) * 2016-02-05 2018-11-09 希望之城公司 施用工程化t细胞以治疗中枢神经系统中的癌症
CN111100204A (zh) * 2019-11-26 2020-05-05 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
CN116593716A (zh) * 2023-07-11 2023-08-15 军科正源（北京）药物研究有限责任公司 检测抗PEG-rhGH中和抗体的方法
WO2025131119A1 (en) * 2023-12-22 2025-06-26 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025167838A1 (en) * 2024-02-08 2025-08-14 Suzhou Bioreinno Biotechnology Limited Company Antibodies, antibody-drug conjugates, and producing methods thereof

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
EP3191519A1 (en) * 2014-09-12 2017-07-19 Biogen MA Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof
EP3230310B1 (en) 2014-12-08 2019-06-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd70 chimeric antigen receptors
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
JP6768011B2 (ja) * 2015-06-23 2020-10-14 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｃｄ１２３抗体との抗体薬物複合体
CN108025071B (zh) * 2015-09-17 2022-11-01 斯克利普斯研究院 双重可变结构域免疫缀合物及其用途
KR20180083874A (ko) * 2015-11-04 2018-07-23 사울 제이. 프라이스맨 Her2를 표적화하는 키메라 항원 수용체
EP3426693A4 (en) 2016-03-08 2019-11-13 Academia Sinica PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
CN110087665A (zh) * 2016-08-03 2019-08-02 H·李·莫菲特癌症中心与研究所公司 Tlr9靶向治疗
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
EP3994177A4 (en) * 2019-07-02 2023-09-20 Telix International Pty Ltd PSMA-BINDING ANTIBODIES WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
EP4096713A1 (en) * 2020-01-31 2022-12-07 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
CA3176255A1 (en) * 2020-03-26 2021-09-30 A28 Therapeutics Inc. Lytic domain fusion constructs, checkpoint inhibitors, and methods of making and using same
US11782685B2 (en) 2020-06-17 2023-10-10 Bank Of America Corporation Software code vectorization converter
US11573775B2 (en) 2020-06-17 2023-02-07 Bank Of America Corporation Software code converter for resolving redundancy during code development
US11347500B2 (en) 2020-06-17 2022-05-31 Bank Of America Corporation Software code converter for resolving conflicts during code development
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
CN113326087B (zh) * 2021-05-19 2023-01-24 翱捷科技股份有限公司 一种lvgl上的中文字库处理方法及装置
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4460564A4 (en) * 2022-01-08 2026-02-11 Carogen Corp MULTI-ANTIGEN THERAPEUTIC VACCINES TO TREAT OR PREVENT CHRONIC HEPATITIS B VIRUS INFECTION
JP2025528832A (ja) * 2022-08-15 2025-09-02 ナヴロジェン インコーポレイテッド 腫瘍免疫抑制性ＩＣＡＭ－１／ＣＤ５４に対し抵抗性のＦｃ改変モノクローナル抗体
CN116514998B (zh) * 2023-05-12 2023-09-15 再少年(北京)生物科技有限公司 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用
CN119331056B (zh) * 2024-09-25 2025-07-22 青岛大学 一种[Tyr3]Octreotate-D-构型溶瘤肽缀合物及其荧光探针的制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033908A1 (en) * 1996-03-13 1997-09-18 Commonwealth Scientific And Industrial Research Organisation Lytic peptides
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2011031477A2 (en) * 2009-08-25 2011-03-17 Esperance Pharmaceuticals, Inc. Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same
WO2011137245A2 (en) * 2010-04-30 2011-11-03 Esperance Pharmaceuticals, Inc. Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
CA1327311C (en) 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
WO1989000194A1 (en) 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
JPH04503306A (ja) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
US5459237A (en) 1990-02-08 1995-10-17 Magainin Pharmaceuticals Inc. Peptide compositions and uses therefor
JPH07504152A (ja) 1990-02-08 1995-05-11 マゲイニン　ファーマスーティカルズ，　インコーポレーテッド 生物活性ペプチドおよび標的細胞、ウイルス、あるいはウイルス感染細胞の成長を抑制する方法
US5792831A (en) 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
JPH06511234A (ja) 1991-06-12 1994-12-15 マゲイニン　ファーマス−ティカルズ，インコーポレーテッド Ｃ末端置換を有する生物活性ペプチド組成物および治療法
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993011783A1 (en) 1991-12-09 1993-06-24 Magainin Pharmaceuticals Inc. Composition and treatment with biologically active peptides and chelating agents
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
AU674525B2 (en) 1992-06-01 1997-01-02 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
WO1994005313A1 (en) 1992-08-31 1994-03-17 Magainin Pharmaceuticals Inc. Treatment of gynecological malignancies with biologically active peptides
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
AU5743194A (en) 1992-12-03 1994-06-22 Magainin Pharmaceuticals, Inc. Treatment of dermatological malignancies with biologically active peptides
WO1994013697A1 (en) 1992-12-07 1994-06-23 Magainin Pharmaceuticals, Inc. Treatment of septic shock with conjugated biologically active peptides
WO1994019369A1 (en) 1993-02-26 1994-09-01 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors
WO1994025616A1 (en) 1993-04-28 1994-11-10 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
WO1994028921A1 (en) 1993-06-04 1994-12-22 Demeter Biotechnologies, Ltd. Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides
US5955573A (en) 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
US5773413A (en) 1993-06-04 1998-06-30 Demeter Biotechnologies, Ltd. Method of combating mammalian neoplasias, and lytic peptides therefor
US5968904A (en) 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
WO1995013085A1 (en) 1993-11-08 1995-05-18 Demeter Biotechnologies Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
CA2117668C (en) 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US5789542A (en) 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
IL114697A0 (en) 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5712379A (en) * 1996-06-07 1998-01-27 California Institute Of Technology Method and compositions for controlling gene expression
JP2001501620A (ja) 1996-10-04 2001-02-06 デメジェン インコーポレイテッド 免疫不全ウイルス感染の治療方法
WO2000053755A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
US6566334B1 (en) 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
AU6587998A (en) 1997-03-27 1998-10-20 Demeter Biotechnologies, Ltd. Ligand/lytic peptide compositions and methods of use
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
CA2294518A1 (en) 1997-07-15 1999-01-28 Magainin Pharmaceuticals Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US6680058B1 (en) 1997-09-03 2004-01-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for contraception in or sterilization of mammals
US6461813B2 (en) 1998-09-21 2002-10-08 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in cell cycle regulation
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
GB0005702D0 (en) 2000-03-09 2000-05-03 Alpharma As Method
AU769482B2 (en) 1999-09-23 2004-01-29 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
CN100500692C (zh) 2000-03-14 2009-06-17 赞塔里斯有限公司 新型lhrh拮抗剂,其制备方法和药物用途
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6875744B2 (en) 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
PT1443966E (pt) 2001-11-15 2007-06-21 Pantarhei Bioscience Bv Método para a prevenção ou tratamento das doenças ginecológicas benignas
EP2289942B1 (en) 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
CA2482995C (en) 2002-04-22 2013-01-29 Dow Global Technologies Inc. Low-cost production of peptides
BRPI0314546B8 (pt) 2002-09-27 2021-05-25 Zentaris Gmbh composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit.
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
EP1599499A2 (en) 2003-02-24 2005-11-30 Dow Global Technologies Inc. Periodic antimicrobial peptides
US7091185B2 (en) 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
US20040167919A1 (en) 2003-02-24 2004-08-26 David Sterling Methods for selectable display of parts of a document on a computer monitor
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
NO20031818D0 (no) 2003-04-23 2003-04-23 Uni I Tromsoe Fremgangsmåte av bioaktiv peptid forberedelse
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7850962B2 (en) * 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0506759D0 (en) 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2007115033A2 (en) 2006-03-31 2007-10-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Layered nanoparticles for sustained release of small molecules
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
US7288622B1 (en) 2006-09-19 2007-10-30 Issar Pharmaceuticals Pvt Ltd Composition for treatment of burns and wounds
US7803755B2 (en) 2006-12-21 2010-09-28 Jesse Jaynes Molecules for the treatment and prevention of fungal diseases
NZ610239A (en) * 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US10093961B2 (en) 2009-12-22 2018-10-09 Esperance Pharmaceuticals Methods for diagnosis of and predicting treatment efficacy of hormone receptor expressing tumors, cancers and neoplasias
WO2012050892A2 (en) 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
HK1213923A1 (zh) 2012-11-15 2016-07-15 Esperance Pharmaceuticals, Inc. 促卵激素(fsh)/胞溶域融合構造體和其製備及使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033908A1 (en) * 1996-03-13 1997-09-18 Commonwealth Scientific And Industrial Research Organisation Lytic peptides
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2011031477A2 (en) * 2009-08-25 2011-03-17 Esperance Pharmaceuticals, Inc. Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same
WO2011137245A2 (en) * 2010-04-30 2011-11-03 Esperance Pharmaceuticals, Inc. Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108779160A (zh) * 2016-02-05 2018-11-09 希望之城公司 施用工程化t细胞以治疗中枢神经系统中的癌症
US12472233B2 (en) 2016-02-05 2025-11-18 City Of Hope Administration of engineered T cells for treatment of cancers in the central nervous system
CN106248971A (zh) * 2016-08-19 2016-12-21 合肥瀚科迈博生物技术有限公司 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途
CN111100204A (zh) * 2019-11-26 2020-05-05 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
CN116593716A (zh) * 2023-07-11 2023-08-15 军科正源（北京）药物研究有限责任公司 检测抗PEG-rhGH中和抗体的方法
CN116593716B (zh) * 2023-07-11 2023-10-13 军科正源（北京）药物研究有限责任公司 检测抗PEG-rhGH中和抗体的方法
WO2025131119A1 (en) * 2023-12-22 2025-06-26 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025167838A1 (en) * 2024-02-08 2025-08-14 Suzhou Bioreinno Biotechnology Limited Company Antibodies, antibody-drug conjugates, and producing methods thereof

Also Published As

Publication number Publication date
JP2016501839A (ja) 2016-01-21
JP6559066B2 (ja) 2019-08-14
US20190367558A1 (en) 2019-12-05
IL238323B1 (en) 2023-07-01
US20140127241A1 (en) 2014-05-08
US20220048951A1 (en) 2022-02-17
EP2914633A1 (en) 2015-09-09
AU2018201996B2 (en) 2019-06-20
BR112015009752A2 (pt) 2017-07-11
EP2914633B1 (en) 2021-12-08
US20250092092A1 (en) 2025-03-20
AU2013337926B2 (en) 2017-12-21
US9492563B2 (en) 2016-11-15
DK2914633T3 (da) 2022-03-14
CA2889475A1 (en) 2014-05-08
EP2914633A4 (en) 2016-07-06
EP4035685A1 (en) 2022-08-03
KR20150095637A (ko) 2015-08-21
US20170121370A1 (en) 2017-05-04
HK1214828A1 (zh) 2016-08-05
KR102460297B1 (ko) 2022-10-28
IL238323A0 (en) 2015-06-30
IL238323B2 (en) 2023-11-01
AU2018201996A1 (en) 2018-04-12
KR20210090298A (ko) 2021-07-19
US10233214B2 (en) 2019-03-19
WO2014070957A1 (en) 2014-05-08
AU2013337926A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
EP2914633B1 (en) Antibody/drug conjugates and methods of use
US20200353032A1 (en) Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
EP3277321B1 (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN102089320B (zh) 溶解结构域融合构建体及其制备和使用方法
CN108473575A (zh) 抗-bcma多肽和蛋白质
US20110124564A1 (en) Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same
AU2013344701A1 (en) Follicle-stimulating hormone (FSH)/lytic domain fusion constructs and methods of making and using same
WO2012050892A2 (en) Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
CN112996816B (zh) 抗糖-muc1抗体及其用途
CN115768455A (zh) 溶解结构域融合构建体、检查点抑制剂、以及制造和使用它们的方法
US20250361299A1 (en) Protease cleavable recombinant bispecific antibodies and compositions and uses thereof
HK40078723A (en) Antibody/drug conjugates and methods of use
HK1214828B (en) Antibody/drug conjugates and methods of use
CA2930243C (en) Epha3 and multi-valent targeting of tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151202

RJ01 Rejection of invention patent application after publication